Agitation Clinical Trial
Official title:
A Double Blinded Randomized Trial of Ketamine Versus Haloperidol for Severe Prehospital Agitation
Verified date | July 2017 |
Source | Minneapolis Medical Research Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research study is being done to find out if one of two drugs, ketamine or haloperidol, is better for treating agitation. Agitation is a state of extreme emotional disturbance where patients can become physically aggressive or violent, endangering themselves and those who are caring for them. Often chemical substances or severe mental illness is involved in this level of agitation. Specifically, the investigators are interested in studying agitation that is treated in the prehospital setting by paramedics. This study's hypothesis is that ketamine is superior to haloperidol for treatment of agitation in the prehospital environment.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 2014 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Clinical diagnosis of severe agitation in the prehospital environment Exclusion Criteria: - Prisoners - Persons known to be younger than 18 years old - Persons suspected to be younger than 18 years old - Obviously gravid women - Persons with profound agitation - Persons who are unable to be transported to the treating facility |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Minneapolis Medical Research Foundation |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time from injection of drug to adequate sedation, defined as a score of 0 or less on the AMSS. | The Altered Mental Status Scale (AMSS) is an integral ordinal scale evaluating both agitation and sedation with scores from -4 to +4. It was developed at our institution and has been internally and externally validated. This scale is a modified version of the Behavioral Activity Rating Scale with additional data points from the Observer's Assessment of Alertness Scale. Effectiveness of sedation will be defined as an AMS score less than or equal to 0. AMSS will be determined by the treating paramedic, who will undergo training as a research associate prior to commencement of the study. Participants will be followed for the duration of agitation, an expected average of 2 hours. |
2 hours | |
Secondary | Number of participants intubated. | Participants will be followed for the duration of agitation, an expected average of 2 hours. Enrolling paramedics or research associates in the Emergency Department will record if the patient is intubated. | 2 hours | |
Secondary | venous pH | Venous blood will be drawn at one and ten minutes post sedation and assessed using point-of-care testing for pH. Enrolling paramedics or research associates in the Emergency Department will record the data. | at one minutes and ten minutes post sedation | |
Secondary | serum potassium | Venous blood will be drawn at one and ten minutes post sedation and assessed using point-of-care testing for potassium concentration. Enrolling paramedics or research associates in the Emergency Department will record the data. | at one minute and ten minutes post sedation | |
Secondary | Total time the participant is a patient in the Emergency Department. | Participants will be followed for the duration of agitation, an expected average of 2 hours. Enrolling paramedics or research associates in the Emergency Department will record both the time the patient arrives in the Emergency Department, and when they leave the Emergency Department. | 2 hours | |
Secondary | Number of patients admitted versus number of patients discharged. | Participants will be followed for the duration of agitation, an expected average of 2 hours. Enrolling paramedics or research associates in the Emergency Department will record if the patient is admitted or discharged. | 2 hours | |
Secondary | venous lactate | Venous blood will be drawn at one and ten minutes post sedation and assessed using point-of-care testing for lactate concentration. Enrolling paramedics or research associates in the Emergency Department will record the data. | at one minute and ten minutes post sedation | |
Secondary | Number of patients experiencing laryngospasm. | Participants will be followed for the duration of agitation, an expected average of 2 hours. Enrolling paramedics or research associates in the Emergency Department will record if laryngospasm occurs. | 2 hours | |
Secondary | Number of patients experiencing dystonia. | Participants will be followed for the duration of agitation, an expected average of 2 hours.Enrolling paramedics or research associates in the Emergency Department will record if dystonia occurs. | 2 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02525991 -
Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting
|
Phase 4 | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT01976754 -
Safety Study of Dexmedetomidine in Septic Patients
|
N/A | |
Completed |
NCT01217541 -
Collaboration Between Department of Old Age Psychiatry and Nursing Homes
|
N/A | |
Withdrawn |
NCT00786318 -
Ziprasidone vs Standard Therapy for Agitated Patients in the ED
|
Phase 4 | |
Not yet recruiting |
NCT05974527 -
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
|
Phase 4 | |
Not yet recruiting |
NCT05522647 -
Detection of Risk Behaviors: Pilot Observational Study With Bedridden and Agitated Patients.
|
||
Recruiting |
NCT02590744 -
Effects of Preoperative Using of Eye Patches on Prevention of Emergence Agitation After Cataract Surgery
|
N/A | |
Recruiting |
NCT02164773 -
Addition of Magnesium Sulfate to Caudal to Prevent Postoperative Emergence Agitation.
|
Phase 4 | |
Completed |
NCT01524367 -
Effect of Single-dose Dexmedetomidine on Emergence Excitement in Adults With Nasotracheal Intubation After Orthognathic Surgery
|
Phase 4 | |
Completed |
NCT01501123 -
Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient
|
N/A | |
Completed |
NCT01021696 -
Pain in Patients With Dementia and Behavioural Disturbances
|
Phase 2/Phase 3 | |
Recruiting |
NCT05397639 -
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
|
Phase 3 | |
Terminated |
NCT03044249 -
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
|
Phase 2 | |
Completed |
NCT05165914 -
Midazolam Effect on Agitation Postnasal Surgery
|
N/A | |
Completed |
NCT04010305 -
Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
|
Phase 1 | |
Completed |
NCT02720705 -
Transbucal Dexmedetomidine for Prevention of Sevoflurane Emergence Agitation in Pre-school Children
|
Phase 2/Phase 3 | |
Completed |
NCT02428283 -
Scalp Nerve Block on Emergence Agitation
|
Phase 4 | |
Completed |
NCT00457366 -
A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
|
Phase 4 | |
Terminated |
NCT00315900 -
Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia
|
Phase 3 |